Objective:To assess the effectiveness and safety of the use of Transcatheter Oily Chemoembolization (TOCE) in treating patients with hepatocellular carcinoma (HCC). Patients and Methods: Prospective study based on 71 patients diagnosed HCC in Hospital of Nghe An Province from 01/2012 to 12/2013. Results: Most of patients with HCC were male (81 percent) and aged over 40 (78.9 percent). The main cause of the disease is hepatitis B virus (77.5 percent). More than half (52.1 percent) had AFP500ng / mL, 59.2 percent had tumor size5cm and mostly solitary liver tumors (78.9 percent). AFP levels decreased from 245.3 average ng/mL to 173.9 ng/mL after 1 month and was 151.2 ng/mL after 2 months (post-embolization). The average size of the tumor decreased from 7.6cm to 6.9cm after 1 month and 5.8cm after 2 months
with 78.1 percent having decreased tumor size after embolization Post embolization syndrome occurred, but most are winthin the limits allowed, no cases of liver failure. Common symptoms include fever after embolization (90. 5 percent), abdominal pain (85.7 percent), the majority are making good progess. Side effects such as nausea, vomiting, hicups and hair loss decreased on their own, with no serious complicatons. The survival rate after 3 months, 6 months and 9 months repectively 77.5 percent, 42.3 percent and 29.6 percent. Conclusion: TOCE is effective in reducing liver tumor size and AFP levels, especially in the case of single and/or small size tumors.